Maraviroc
Paul G. Auwaerter, M.D., Paul A. Pham, Pharm.D. BCPS
INDICATIONS
INDICATIONS
INDICATIONS
FDA
FDA
Only recommended for patients with CCR5-tropic HIV-1 infection.
- Used with other ARVs in ART-experienced adult patients infected with CCR5 (R5)-tropic HIV-1.
- Used in combination with other ARVs in ART-naive adult patients infected with CCR5 (R5)-tropic HIV-1 (not a DHHS preferred first-line agent)
- FDA-approved for adults and pediatric patients 2 years and older weighing at least 2 kg.
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2025 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.